Shares of Moderna surged over 150% following successful trials of a personalized melanoma vaccine, leading to a sharp reassessment of the company's market prospects.

Shares of Moderna surged over 150% following successful trials of a personalized melanoma vaccine, leading to a sharp reassessment of the company's market prospects.

@ostorozhno_novosti 19 Aug 2026, 16:20

Moderna's shares rose by 150% in a day following the announcement of successful trials for a melanoma vaccine, increasing the company's market capitalization to over $55 billion.

@meduzalive 19 Aug 2026, 16:04